» Articles » PMID: 8621142

Predictive Score for the Development of Hepatocellular Carcinoma and Additional Value of Liver Large Cell Dysplasia in Western Patients with Cirrhosis

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1996 May 1
PMID 8621142
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

The aim of this study was to identify high-risk patients for hepatocellular carcinoma (HCC). Among 151 patients with histologically proven cirrhosis hospitalized from 1987 to 1990 and prospectively followed-up until June 1994, 31 developed HCC. We assessed the predictive value of 22 variables recorded at enrollment for HCC occurrence by the log rank test and the Cox proportional hazards model. Six clinical and biological variables summarized predictive information of HCC: age > or = 50 years (P = .01), male (P = .01), large esophageal varices (EV) (P = .03), prothrombin activity < 70% (P = .04), serum alpha-fetoprotein (AFP) > or = 15 ng/L (P = .06), and anti-hepatitis C virus antibodies (P = .08). A clinicobiological predictive score identified two groups of patients at low (n = 67; 3-year cumulative incidence, 0%) and high risk for HCC (n = 84; 3-year cumulative incidence, 24%). The predictive value of this score was confirmed using an independent population of 49 patients with cirrhosis. Furthermore, liver large-cell dysplasia (LCD) had an additional predictive value in high-risk patients (P = 10(-4), which thus helped to define a subgroup at very high risk for HCC (n = 12; 3-year cumulative incidence, 72%). In Western patients with cirrhosis, a limited number of usual variables can identify a group of patients at high risk for HCC. Among these patients, liver biopsy allows for the determination a subgroup of patients at very high risk for HCC requiring intensive screening or preventive measures.

Citing Articles

Hepatocellular carcinoma hosts cholinergic neural cells and tumoral hepatocytes harboring targetable muscarinic receptors.

Hernandez C, Verzeroli C, Roca-Suarez A, Farca-Luna A, Tonon L, Esteban-Fabro R JHEP Rep. 2024; 7(1):101245.

PMID: 39717507 PMC: 11663970. DOI: 10.1016/j.jhepr.2024.101245.


Platelet-Activating Factor Promotes the Development of Non-Alcoholic Fatty Liver Disease.

Yin H, Shi A, Wu J Diabetes Metab Syndr Obes. 2022; 15:2003-2030.

PMID: 35837578 PMC: 9275506. DOI: 10.2147/DMSO.S367483.


Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Stimac D Cochrane Database Syst Rev. 2021; 4:CD013346.

PMID: 33855699 PMC: 8078581. DOI: 10.1002/14651858.CD013346.pub2.


Pathological predictive factors for late recurrence of hepatocellular carcinoma in chronic liver disease.

Nahm J, Lee H, Kim H, Yim S, Shin J, Yoo J Liver Int. 2021; 41(7):1662-1674.

PMID: 33638929 PMC: 8774293. DOI: 10.1111/liv.14835.


Liver-related effects of chronic hepatitis C antiviral treatment.

Laursen T, Sandahl T, Kazankov K, George J, Gronbaek H World J Gastroenterol. 2020; 26(22):2931-2947.

PMID: 32587440 PMC: 7304101. DOI: 10.3748/wjg.v26.i22.2931.